Summary
Alembic Pharmaceuticals Limited - Q3 FY26 Earnings Call Summary Thursday, February 05, 2026 5:00 PM
Event Participants
Executives Ajay Kumar Desai (Senior VP-Finance), G. Krishnan (CFO), Pranav Amin (Managing Director), R.K. Baheti (Executive Director), Shaunak Amin (Managing Director)
Analysts Candice Pereira (Dolat Capital), Damayanti (HSBC), Rahul (IIFL)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹1,876 crores | +11% YoY; driven by volume expansion, new launches, and ex-U.S. traction, offset by pricing pressure. |
| India Branded Revenue | ₹652 crores | +6% YoY; growth seen in Gynaecology, Ophthalmology, and Animal Healthcare segments. |
| ROW Revenue | - | +36% YoY; reflects strategic geographic expansion and focused execution. |
| U.S. Revenue | - | +6% YoY; supported by volume and new launches despite persistent pricing challenges. |
| Gross Margin | 72% | -200 bps YoY; moderation due to change in product mix and pricing pressure, mitigated by cost efficiency. |
| EBITDA (Pre-R&D) | ₹464 crores | +20% YoY; 25% margin reflects improved operating leverage and prudent discretionary spend. |
| R&D Expenses | ₹165 crores | +33% YoY; currently at ~9% of revenue, in line with FY26 guidance of ₹600-650 crores. |
| PAT (Pre-exceptional) | ₹168 crores | +21% YoY; reflects underlying revenue growth and better facility utilization. |
| Net Debt | ₹1,213 crores | Marginal decline compared to previous quarter; Net Working Capital at ₹2,944 crores. |
| ANDA Filings/Approvals | 270 Filings | 1 filing and 7 approvals in Q3; cumulative 23 full approvals and 20 tentative approvals. |
Geographic & Segment Commentary
- India Branded Business: Delivered 6% growth, currently performing below market rates. Growth is primarily driven by acceleration in Gynaecology, Ophthalmology, and Animal Healthcare. Management expects performance to align with market growth by Q1 FY27 through operational execution.
- U.S. Generics: Achieved 6% growth despite significant pricing headwinds. Focus is shifting towards complex areas including injectables, peptides, and ophthalmic products. The company plans to launch 4-5 additional products in Q4 FY26.
- Ex-U.S. (ROW) & API: ROW markets grew strongly at 36% due to geographic expansion. The API business continues to face pricing challenges similar to international generics, though volume momentum remains stable.
Company-Specific & Strategic Commentary
- Branded U.S. Entry (Pivya): Launch of the first branded oral antibiotic (Pivya) for UTIs scheduled for Q4 FY26. While near-term profitability may be impacted by marketing and royalty costs, management sees this as a strategic shift toward a part-branded U.S. business over the next 12-18 months.
- Specialty Utilization: Executed several out-licensing and manufacturing agreements to scale utilization of new injectable and oncology facilities. Management expects these contracts to ramp up throughput over the next 12 to 18 months.
- Cost & Efficiency: Sustained cost-improvement programs in the International Business helped keep gross margins within the target range of 70%-75%. Operating leverage improved as capacity utilization increased across facilities.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| U.S. Revenue Growth | 10% - 15% (FY27-28) | Expected to be driven by complex injectables, ophthalmics, and peptides. |
| R&D Spend | 8% - 9% of Revenue | Sustained commitment to pipeline development and complex areas. |
| India Market Growth | Catch up by Q1 FY27 | Driven by improved operational execution rather than just new launches. |
| Product Launches | 4 - 5 products (Q4 FY26) | Pipeline focus on early-entry opportunities like First-to-File and NCE-1. |
Risks & Constraints
| Risk | Context |
|---|---|
| Pricing Pressure | Persistent pricing headwinds in U.S. generics and API businesses are compressing gross margins, though volume growth acts as a partial offset. |
| Domestic Underperformance | The India business has grown at a “tepid” pace recently. Management attributes this to conservative doctor-spend policies (UCPMP) and post-COVID normalization. |
| Operational Drag | The launch of branded Pivya in the U.S. will incur immediate field force and royalty costs, potentially dragging margins until prescription share scales. |
| Regulatory Compliance | Management noted extreme sensitivity to the New Labour Code and UCPMP ethical norms, which may limit aggressive marketing tactics compared to peers. |
Q&A Highlights
India Growth Strategy
- Question: When will India growth catch up to the market given recent underperformance? (Damayanti, HSBC)
- Answer: Growth should align with market rates by Q1 FY27, driven by operational execution rather than just new products (Shaunak Amin).
U.S. Branded Launch (Pivya)
- Question: How will Pivya succeed given the reimbursement challenges faced by other AMR products? (Damayanti, HSBC)
- Answer: Pivya sits in a “sweet spot” for efficacy and cost. The team is currently working on reimbursement and co-pay structures for a Q4 launch (Pranav Amin).
R&D and Margin Trajectory
- Question: Will R&D remain at 9% of sales and how will margins look for FY27? (Candice Pereira, Dolat Capital)
- Answer: R&D will likely stay in the 8%-9% range. Margin expansion from better capacity utilization should provide a cushion for Pivya’s launch expenses (Pranav Amin & G. Krishnan).
Domestic Market Dynamics
- Question: Why has growth been tepid for 3-4 years and do we need more field force? (Rahul, IIFL)
- Answer: We were likely too conservative regarding doctor spend and UCPMP norms compared to the market. No large field force expansions are planned currently; the focus is on fixing fundamental operational issues (Shaunak Amin).
Key Takeaway
Alembic Pharmaceuticals delivered a steady Q3 FY26 with 11% revenue growth to ₹1,876 crores, characterized by a sharp 36% surge in ROW markets and resilient 6% growth in the U.S. despite pricing headwinds. While the India Branded business grew at a modest 6%, management is pivoting toward operational excellence to match market growth rates by early FY27. Strategically, the company is transitioning toward complex generics and its first branded U.S. launch, Pivya, which is expected to scale over 12-18 months. R&D remains a core focus at 9% of revenue, targeting high-value injectables and peptides to improve facility utilization. Although gross margins moderated to 72% due to pricing pressures and product mix, improved operating leverage led to a 20% jump in EBITDA. Investors should monitor the ramp-up of the U.S. branded portfolio and the recovery of domestic growth as key catalysts.
Want more insights like this?
Subscribe to get deep dives delivered to your inbox.
More Earnings Summaries
Explore more Q3 FY26 earnings call analyses: